Michael Druckman
Partner and Chair of Hogan Lovells’ Cell, Tissue, and Gene Therapies Industry Group
Mike Druckman leverages his prior experience at the FDA – and what he has learned since then while extricating companies from a full range of regulatory challenges – to anticipate and prevent life science clients from getting into trouble in the first place. Mike works closely with companies developing stem cells, cord blood, placental tissues, gene therapies, proteins, and other cellular products to help people with serious health problems.